与神经调节素1 (NRG1) 融合的固体瘤患者的阿法替尼:来自向药物和分析利用注册表 (TAPUR) 研究的病例系列
J Rodon1, M Rothe2, P K Mangat2
1Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA.
ESMO open
|April 11, 2025
概括
阿法替尼在患有先进的固体瘤,含有NRG1融合的患者中显示出有前途的抗瘤活性. 这种向治疗实现了持续的疾病控制,表明了进一步临床研究的潜力.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 有针对性的治疗.
背景情况:
- 塔普尔试验是一项II期篮子研究,评估了基因组改变的晚期癌症的向药物.
- 本报告侧重于四名NRG1融合阳性瘤患者,他们接受了阿法替尼治疗.
研究的目的:
- 评估阿法提尼布在患有晚期固体瘤和NRG1融合的患者中的抗瘤活性.
- 评估疾病控制,客观反应,反应持续时间和安全性.
主要方法:
- 纳入了四名患有晚期固体瘤 (结肠直肠,非小细胞肺,胰腺) 和NRG1融合的患者.
- 资格包括可测量的疾病,ECOG 0-2,足够的器官功能,没有标准治疗选择.
- 疾病控制 (DC) 是主要终点,定义为客观反应或至少16周的稳定疾病 (SD16+).
主要成果:
- 在四名可评估患者中观察到一个部分反应和两个SD16+病例.
- 一名患者获得了134周的持久稳定疾病,并保持了生命.
- 没有报告与药物相关的3-5级不良事件或严重不良事件.
结论:
- 在这个小群体中,阿法替尼表现出有前途的抗瘤活性和持久的疾病控制.
- 这些发现支持对阿法提尼布用于NRG1融合的晚期固体瘤的进一步研究.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
09:49Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
9.5K
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...